Renaissance Capital logo

Upstream Bio Priced, Nasdaq: UPB

Phase 2 respiratory biotech developing an antibody that targets the TSLP receptor.

Industry: Health Care

Latest Trade: $26.38 0.00 (0.0%)

First Day Return: +29.4%

Return from IPO: +55.2%

Industry: Health Care

We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (“TSLP”), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients. We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (“CRSwNP”) and plan to initiate development in chronic obstructive pulmonary disease (“COPD”). Our experienced team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care.
more less
IPO Data
IPO File Date 09/18/2024
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 15.0
Deal Size ($mm) $255
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/10/2024
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 15.0
Deal Size ($mm) $255
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
J.P. Morgan
TD Cowen
more
Company Data
Headquarters Waltham, MA, United States
Founded 2021
Employees at IPO 38
Website www.upstreambio.com

Upstream Bio (UPB) Performance